Kaken Pharmaceutical Co., Ltd. (KKPCF)
| Market Cap | 989.15M |
| Revenue (ttm) | 627.96M |
| Net Income (ttm) | 93.12M |
| Shares Out | n/a |
| EPS (ttm) | 2.44 |
| PE Ratio | 10.62 |
| Forward PE | n/a |
| Dividend | 1.30 (4.87%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 1,577 |
| Average Volume | 5 |
| Open | 28.00 |
| Previous Close | 26.78 |
| Day's Range | 26.78 - 28.00 |
| 52-Week Range | 22.30 - 29.20 |
| Beta | 0.03 |
| RSI | 97.49 |
| Earnings Date | May 12, 2025 |
About Kaken Pharmaceutical
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger... [Read more]
Full Company ProfileFinancial Performance
In 2024, Kaken Pharmaceutical's revenue was 94.04 billion, an increase of 30.52% compared to the previous year's 72.04 billion. Earnings were 13.95 billion, an increase of 73.77%.
Financial numbers in JPY Financial StatementsNews
Top 3 Health Care Stocks That May Crash In Q2
As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicat...
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediat...